Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Alessandra B Alió Saenz"'
1
Clinical Pharmacology and Safety of Trifarotene, a First‐in‐Class RARγ‐Selective Topical Retinoid
Autor: Khaled Benkali, Michael Graeber, Nathalie Wagner, Alessandra B Alió Saenz, Michel Poncet
Publikováno v: Journal of Clinical Pharmacology
Trifarotene is a new drug with retinoic acid receptor activity and selectivity for retinoic acid receptor‐γ. The reported studies aimed at assessing the clinical pharmacology and safety of trifarotene. The clinical pharmacology of topical trifarot
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a386d3826f9b08b4cfb85ac592c0b84
http://europepmc.org/articles/PMC7187247
Zobrazit plný text záznamu
2
Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne
Autor: Lajos Kemény, Fran E Cook-Bolden, Ulrike Blume-Peytavi, Michael Graeber, Phoebe Rich, Faiz Ahmad, Joseph F. Fowler, Zoe Diana Draelos, Lawrence F. Eichenfield, Alessandra B Alió Saenz, Thomas Dirschka, Emil Tanghetti
Publikováno v: Journal of the European Academy of Dermatology and Venereology
Author(s): Blume-Peytavi, U; Fowler, J; Kemeny, L; Draelos, Z; Cook-Bolden, F; Dirschka, T; Eichenfield, L; Graeber, M; Ahmad, F; Alio Saenz, A; Rich, P; Tanghetti, E | Abstract: BackgroundTreatment for both facial and truncal acne has not sufficient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1197a48788aba905ca964bf4d4bc369
http://europepmc.org/articles/PMC7004112
Zobrazit plný text záznamu
5
Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study
Autor: Masahiro Yamada, Hirofumi Hashimoto, Makoto Ono, Makoto Kawashima, Alessandra B Alió Saenz
Publikováno v: The Journal of Dermatology. 41:795-801
Benzoyl peroxide (BPO) as an anti-acne medication is not yet approved in Japan. This study evaluated the efficacy and safety of a once-daily topical application of BPO 3% gel versus an inert vehicle gel in Japanese acne patients. Three hundred and si
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::020feb27305c22f14ecd036fa00ae309
https://doi.org/10.1111/1346-8138.12580
Zobrazit plný text záznamu
6
Systemic exposure to benzoic acid and hippuric acid following topical application of clindamycin 1%/benzoyl peroxide 3% fixed-dose combination gel in Japanese patients with acne vulgaris
Autor: Hiroko Ino, Setsuo Hasegawa, Naoki Takahashi, Alessandra B Alió Saenz, Hirofumi Hashimoto, Akira Wakamatsu, Norie Nakahara
Publikováno v: Clinical Pharmacology in Drug Development. 4:18-24
Clindamycin 1%/benzoyl peroxide 3% fixed-dose combination gel (CLDM/BPO3%) is a topical product for the treatment of acne vulgaris. In this study, plasma and urine concentrations of benzoic acid (BA) and hippuric acid (HA) were analyzed to estimate t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b232e7cca96e19fad9e448478f88474b
https://doi.org/10.1002/cpdd.125
Zobrazit plný text záznamu
7
Bioavailability of Clindamycin From a New Clindamycin Phosphate 1.2%-Benzoyl Peroxide 3% Combination Gel
Autor: Terry M. Jones, Stacy Jasper, Alessandra B Alió Saenz
Publikováno v: Clinical Pharmacology in Drug Development. 2:33-47
A new topical fixed-dose combination product containing clindamycin (1%, formulated as 1.2% clindamycin phosphate, CLNP 1.2%) with low strength (3%) benzoyl peroxide (BPO) in a methylparaben-free gel vehicle (CLNP 1.2%-BPO 3%-MPF) has been developed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff545929a1970f979c05a22f67ff3a06
https://doi.org/10.1002/cpdd.7
Zobrazit plný text záznamu
8
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies
Autor: Steven R, Feldman, Cary P, Werner, Alessandra B, Alió Saenz
Publikováno v: Journal of drugs in dermatology : JDD. 12(4)
Tazarotene 0.1% gel and cream are effective topical treatments for acne. Tazarotene foam, 0.1% was developed to provide an alternative, safe, and effective formulation.To evaluate efficacy and tolerability of tazarotene foam, 0.1% in adults and adole
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a6b123e48fca17433e01e17286ccc5aa
https://pubmed.ncbi.nlm.nih.gov/23652892
Zobrazit plný text záznamu
9
Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris
Autor: Cary P. Werner, Michael Jarratt, Alessandra B Alió Saenz
Publikováno v: Clinical drug investigation. 33(4)
Tazarotene, a retinoid pro-drug, is available in gel, cream and foam for the topical treatment of acne vulgaris. This single-centre, randomized, open-label study assessed relative bioavailability of its active metabolite tazarotenic acid after dosing
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31577babc3a76d47ac5416cbf998d81f
https://pubmed.ncbi.nlm.nih.gov/23456673
Zobrazit plný text záznamu
10
Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies
Autor: Daniel J, Hogan, Alessandra B Alió, Saenz
Publikováno v: Cutis. 90(5)
Two phase 1 patch studies were conducted to evaluate tazarotene foam 0.1% for phototoxic (study A) and photoallergic (study B) potential. In study A, 38 participants were exposed to patches containing tazarotene foam 0.1%, vehicle foam, or no foam (b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cb6954694ac394bee43b2fbf3bd6d08f
https://pubmed.ncbi.nlm.nih.gov/23270200
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje